Medical Condition News

RSS

American Asthma Foundation awards $750,000 for asthma research

Dr. Serpil Erzurum, one of the nation's leading experts in asthma, has been awarded $750,000 by the American Asthma Foundation (AAF). Dr. Erzurum will collaborate with experts in nuclear medicine and physics to develop an innovative way for clinicians to observe changes in the lungs of patients during an asthma attack.

9 Sep 2009

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

9 Sep 2009

St. Jude Medical's Brio neurostimulator receives CE Mark approval

St. Jude Medical, Inc. (NYSE:STJ) today announced CE (Conformité Européenne) Mark approval of the Brio™ neurostimulator, the world’s smallest, longest-lasting rechargeable deep brain stimulation (DBS) device for treating the symptoms of Parkinson’s disease. A 67-year-old man who has suffered from Parkinson’s disease for more than 26 years became the first person to be implanted with the Brio neurostimulator.

9 Sep 2009

New television program to raise awareness about cardiovascular diseases in women

Research shows that 80 percent of cardiac events in women could be prevented if women make the right choices for their hearts, involving diet, exercise and abstinence from smoking.

9 Sep 2009

CEO Cancer Gold Standard accreditation for ASCO

The American Society of Clinical Oncology (ASCO) has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

9 Sep 2009

VIVUS' Phase 3 studies find Qnexa effective in tackling obesity

VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo.

9 Sep 2009

Dana-Farber Cancer Institute reaches milestone: $1 billion raised in campaign

Dana-Farber Cancer Institute today announced it has reached its $1 billion Mission Possible: The Dana-Farber Campaign to Conquer Cancer fundraising goal one year early. The first hospital in New England to set and reach a $1 billion campaign goal, Dana-Farber will continue to raise funds for campaign priorities until Sept. 30, 2010, when the campaign was scheduled to end.

9 Sep 2009

SupportSight free seminar for people affected by macular degeneration

Chester County Eye Care Associates has joined with the Macula Vision Research Foundation (MVRF) to sponsor a SupportSight seminar in West Chester on September 26th.

9 Sep 2009

Campaign launched to tackle childhood obesity

Urging children to get at least 60 minutes of physical activity each day, Pennsylvania Health Secretary Everette James and Education Secretary Gerald Zahorchak today helped to kick off the NFL Play 60 national youth health and fitness campaign.

9 Sep 2009

International Institute of Biomedical Sciences and Technology established for a global research initiative

Upstate Medical University in Syracuse, New York, the Technion-Israel Institute of Technology in Haifa, Israel, and National Cheng Kung University in Tainan City, Taiwan, have announced the creation of the International Institute of Biomedical Sciences and Technology that will facilitate the collaboration of research across three continents and accelerate the development of novel bioengineering, diagnostic and biomedical products for the treatment and cure of disease, officials said today.

9 Sep 2009

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma AG, Germany. The milestone was triggered by Bayer’s submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MN-IC, an ADC for solid tumors.

9 Sep 2009

Psoriasis Walk organized to support the research and education programs of Psoriasis Cure Now

The first-ever New Jersey Psoriasis Walk will take place in Paramus this Saturday, September 12, 2009, at beautiful Van Saun Park. The walk, to support the research and education programs of the nonprofit Psoriasis Cure Now, will include entertainment, information booths on psoriasis treatments, and a chance to meet and learn from others living with psoriasis and psoriatic arthritis. Janine Natoli of Little Falls is volunteer Chair of the NJ Psoriasis Walk, on the Web at http://www.PsoriasisWalkNJ.org.

9 Sep 2009

1.4 million Nigerians over the age of 40 will become blind by 2020: Study

By 2020, 1.4 million Nigerians over age 40 will lose their sight, and the vast majority of the causes are either preventable or treatable, according to the Nigeria National Blindness and Visual Impairment Study Group.

9 Sep 2009

Daily intake of fruits and vegetables indicates higher cognitive performance in individuals

Researchers at the Institute of Biochemistry and Molecular Biology I of the Heinrich-Heine University, Düsseldorf, Germany, investigated the relationship between fruit and vegetable intake, plasma antioxidant micronutrient status and cognitive performance in healthy subjects aged 45 to 102 years. Their results, published in the August issue of the Journal of Alzheimer's Disease, indicated higher cognitive performance in individuals with high daily intake of fruits and vegetables.

9 Sep 2009

Moisturizing skin helps manage Keratosis Pilaris

KP is a genetic skin condition that affects 40 percent of the world's population, often resulting in patches of dry skin, and little red bumps, on the arms and legs. KP is most prevalent in the teenage years but may continue throughout adulthood. There is no cure for Keratosis Pilaris.

9 Sep 2009

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

Active, but non-invasive breast cancer is set free to roam as invasive breast cancer when an overexpressed protein converts it to a different cell type, scientists at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of the journal Cancer Cell.

9 Sep 2009

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.

9 Sep 2009

Safeway raises funds to support neuromuscular disease medical research and therapies

Safeway Inc. announced today it has raised a record $10.2 million to support medical research and services for the millions of people living with neuromuscular diseases. The funds were raised during Safeway’s annual Muscular Dystrophy Association (MDA) campaign, a five-week endeavor to highlight the need to find cures and treatments for muscular dystrophy and related diseases, and presented during the Jerry Lewis MDA Telethon in Las Vegas Labor Day weekend.

9 Sep 2009

Cardiac Network increases the number of sites for its research study

Cardiac Network, Inc. (PINKSHEETS: CNWI) reported today that it has expanded the number of sites included in its research study support with Southern California Permanente Medical Group.

9 Sep 2009

First results of European survey of cancer patients' experience of breakthrough pain presented at EFIC

The first results of the first European survey of cancer patients' experience of breakthrough pain were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

9 Sep 2009